Cochrane · systematic review · CD006242
Trastuzumab‐containing regimens for metastatic breast cancer
Balduzzi, S, Mantarro, S, Guarneri, V, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings for the main comparison
Population: patients with HER2‐positive metastatic breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival | HR 0.82 [0.71, 0.94] | 5 studies · 1309 participants | Moderate |
Progression‐free survival | HR 0.61 [0.54, 0.7] | 7 studies · 1489 participants | Moderate |
Congestive heart failure | RR 3.49 [1.88, 6.47] | 7 studies · 1459 participants | Moderate |